China Medical System

China Medical System Holdings Limited (CMS) (康哲药业) operates as a pharmaceutical innovation and commercialization platform, with the core objective of delivering competitive products and services that address unmet healthcare needs.

Leveraging nearly three decades of experience in the Chinese pharmaceutical market, CMS integrates capabilities across the entire product lifecycle – from identifying clinical demands and managing projects to clinical development and commercialization.

The company’s R&D strategy centers on both Collaborative R&D and In-house R&D, aimed at developing innovative products, including global First-in-class and Best-in-class drugs. CMS maintains a robust product pipeline focused on specialty therapeutic areas such as cardio-cerebrovascular, central nervous system, gastroenterology, dermatology, and ophthalmology. Several of its innovative drugs have received marketing approval in China.

CMS's commercialization system features extensive channel coverage and specialized promotional teams, contributing to strong market positions for its major marketed products. While the company’s primary market remains China, it is expanding into Southeast Asia, aiming to establish an integrated “R&D, manufacturing, and commercialization” presence in the region.

China Medical System Holdings Limited is an exempted company incorporated in the Cayman Islands on December 18, 2006. Its shares are primarily listed on the Hong Kong Stock Exchange (HKSE) since September 28, 2010 (Stock Code: 867), and secondarily listed on the Singapore Exchange (SGX) since July 15, 2025 (Stock Code: 8A8).